Trial
NCT05304130
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Arthritis, Rheumatoid
Intervention
Otilimab
Why stopped
This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-26